Genfit to Present Seven Posters at EASL 2026 Congress on ACLF
Genfit announced on Monday a strong scientific presence at the EASL 2026 congress, with seven accepted posters covering its main assets in acute decompensation on cirrhosis. This participation reflects the strengthening of its strategic positioning in ACLF, elevated to a common priority by the international hepatological ecosystem.
Seven Posters and Real-World Data at the Heart of the Presentation
Genfit's presence revolves around two main themes. The first concerns scientific data on G1090N (nitazoxanide) and SRT-015 (ASK1 inhibitor), examining differential activity against organ failures and immune responses in models of alcoholic decompensation. The second covers real-world data: analysis of gaps in hospital management and access to gastroenterologists, clinical impact of bacterial infections on 4.97 million admissions, efficacy of treatment for hepatic encephalopathy, and rapid recognition of the ICD-10 K76.82 code in American registries. The GNS561 program in cholangiocarcinoma will not be presented this year, as dose escalation continues in phase 1. This candidate is expected to be showcased later at specialized oncological congresses.
ACLF Designated as a Global Strategic Priority
Two key events will mark this participation. On May 26, EASL and its sister societies (AASLD, APASL, ALEH, SOLDA) will hold the first global consensus meeting to harmonize the definition of ACLF, aiming to overcome persistent regional divergences. On May 27, Genfit and the European Foundation for the Study of Chronic Liver Failure will co-organize the annual 'ACLF Insights' event, featuring presentations by Dr. Veronica Miller (University of Berkeley, Forum for Collaborative Research) and Dr. Richard Moreau (INSERM, EF CLIF) on the governance framework of the recently launched ACLF Program, complemented by discussions on translational science and advancements in Genfit's portfolio.
NIS2+ Positioned on MASH Diagnosis in an Expanding Market
MASH will be a central theme at the EASL 2026 congress, with approximately 250 abstracts including four in 'late breaking'. Although Genfit is not presenting new data this year, its non-invasive diagnostic technology NIS2+ is already included in the EASL-EASD-EASO recommendations. With the expansion of the MASH therapeutic market and the successes of first-year commercialization, large-scale patient identification becomes a major strategic challenge, reinforcing the positioning of this technology.
